BioPharm International integrates the science and business of biopharmaceutical development, and manufacturing. We provide practical, peer-reviewed technical articles to enable biopharmaceutical professionals to perform their jobs more effectively. We believe that technical decisions are also business decisions and give readers the tools to make both sound business and technical decisions.

More than 30,200 readers worldwide count on BioPharm International for emerging tools and trends for formulating, developing, delivering, and manufacturing pharmaceutical products through biotechnology. Readers are involved in product and process development, manufacturing, quality control/quality assurance, analytical technologies, regulatory affairs, plant and project engineering and design, and corporate management for the entire scope of biopharmaceutical products, including therapeutic peptides, proteins, nucleic acids, and cells for cell therapies and regenerative medicine, as well as both therapeutic and prophylactic vaccines.

BioPharm International articles help keep our readers up-to-date on technical and regulatory topics including:
• upstream processing (protein expression, fermentation & cell culture) and process development
• downstream processing (separation and purification) and process development;
• drug formulation and delivery;
• validation;
• GMP compliance and quality control;
• analytical technologies;
• scale-up strategies; and
• facilities design and expansion.

We also cover business topics such as:
• supply-chain management;
• sourcing and outsourcing;
• project management;
• partnerships; and
• intellectual property management.

BioPharm International’s readers are also its authors. You can help us meet your needs by submitting manuscripts that offer technical and scientific discussions of ongoing drug development challenges and solutions.

Submitted manuscripts should be sufficiently novel to be of interest to an experienced audience. Articles should be data driven and provide sufficient technical detail to support the main thesis or should offer a novel synthesis of existing data. Topics should be timely and useful and should focus on the development of peptides, monoclonal antibodies, fusion proteins, other therapeutic proteins, nucleic acids, vaccines, cells for cell therapy, and any other class of biotechnologically generated molecular class.

Peer-review Articles
Peer-reviewed research articles in BioPharm International present novel scientific findings and data that significantly advance a technology, a process, a synthesis, a formulation. The articles set out a hypothesis, describe experiments (including proper control experiments), present data derived from those experiments, offer a discussion of the data, and then draw a conclusion from them. BioPharm International follows peer-review procedures standard for scholarly and academic journals.

BioPharm International will consider original technical and scientific review articles that have never been previously published in any format, print or electronic, and are not under consideration at any other journal during the period they’re under review at BioPharm International.

To contribute, view BioPharm International's Peer-Review Article Author Guidelines or Author Guidelines for Technical articles and Supplements [downloadable PDFs].

View the 2013 Editorial Calendar.